Organetix, Inc. (OTC BB: OGTX), a developer of nutraceuticals and bioceuticals initially targeting Hepatitis C, Cirrhosis, other diseases of the human liver, and alleviating symptoms of patients undergoing chemotherapy, announced today that it will initiate testing a nutraceutical anti-viral formula on the Avian Influenza (Bird Flu) and the Avian Influenza (H5N1) virus.

Organetix is actively researching anti-viral plant based formulas in an attempt to develop a nutraceutical treatment that could address a serious flu pandemic.

In announcing the initiative, Brad Clarke, President and Chief Executive Officer of Organetix, said, "Companies and governments need to be working together in the event that a flu pandemic arises in the future. We need to be prepared. We need to investigate all products that may be able to eradicate the virus or lessen its ability to destroy human life."

For more information on the Avian Influenza please visit the Centers for Disease Control and Preventions website: www.cdc.gov/flu or call 1-800-CDC-INFO; for further information the following web sites can be accessed:

http://www.cdc.gov/flu/avian/gen-info/pandemics.htm
http://www.who.int/csr/disease/avian_influenza/en/

About Organetix, Inc.

Organetix is a biotechnology company that has the exclusive worldwide license for A4+L, a proprietary formula targeting diseases of the human liver. This liver product has been used specifically to treat patients with Hepatitis C and to assist chemotherapy patients. Limited research shows it is regenerating liver tissue thus allowing the liver to begin functioning again despite years of damage. This proprietary liver product does not cure Hepatitis C but has the capability of regenerating the liver and may someday lead us to a cure.

Organetix will specialize in researching, developing and patenting bioactive compounds and their unique formulas and processes from plants having a unique history of medicinal use. Organetix believes that nutraceuticals and bioceuticals are the foundations for the new and exciting drugs to be discovered in the 21st Century.

Additional information on Organetix is available on its web site: www.organetixinc.com

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events, or otherwise.

Company Contact Brad Clarke President and CEO Phone: 212.758 4454 ext # 224 Email: Email Contact Organetix Inc. 15th Floor 405 Park Avenue New York, NY 10022 Investor Relations Contact: Michael Dodge / Robert Giordano ROI Group Associates, Inc. Phone: 212.495.0200 x 17 Email: Email Contact Email Contact www.roiny.com